NCT06455748招募中不适用
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
Yongyong MA1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Hematologic Overall Remission Rate (ORR)
研究概览
简要总结
This is a prospective and single arm clinical study. The goal of this clinical trial is to observe and evaluate the efficacy and safety of Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone in the treatment of patients with newly diagnosed AL amyloidosis.
详细描述
Primary objective:
Hematologic overall remission rate (ORR) as defined by the criteria in the Chinese Guidelines for the Diagnosis and Treatment of Systemic Light Chain Amyloidosis, 2021 edition.
Secondary objective:
- organ remission rate as defined by the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Systemic Light-Chain Amyloidosis 2021 Edition, hematologic complete remission (CR) rate, very good partial remission (VGPR) rate, progression free survival (PFS), overall survival (OS), and negative rate of microscopic residual disease (MRD).
- safety of combination therapy regimens.
Exploratory purpose:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-80 years old, diagnosed with primary amyloidosis of AL tissue;
- •ECOG PS score 0-2 points;
- •Measurable disease: The difference between affected and unaffected FLC is>20 mg/L, and the serum immunoglobulin kappa λ FLC ratio is abnormal;
- •Having sufficient organ and bone marrow function, defined as follows:
- •Blood routine: Absolute neutrophil count ≥ 1.0 x 10 ^ 9/L, platelet count ≥ 50 x 10 ^ 9/L;
- •Blood biochemistry and electrolytes: ALT and AST both ≤ 3 times the upper limit of normal, total bilirubin ≤ 1.5 times the upper limit of normal, creatinine clearance rate ≥ 30 mL/min, serum corrected calcium ≤ 14.0 mg/dL (≤ 3.5 mmol/L) or free ion calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L);
- •Women of childbearing age must agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study period and within 3 months after the end of the study; Within 7 days prior to enrollment in the study, the serum or urine pregnancy test was negative and must be a non lactating patient; In addition, if the subject misses their menstrual period or experiences abnormal menstrual bleeding, the researcher can conduct a pregnancy trial at any time during the study period;
- •Men must agree to use contraceptive measures during the study period and within 3 months after the end of the study period;
- •The patient agrees to participate in the clinical trial and signs an informed consent form.
排除标准
- •Non AL amyloidosis;
- •Known to be allergic, hypersensitive or intolerant to monoclonal antibodies or human derived proteins, daretozumab or its excipients, or known to be allergic to mammalian derivatives;
- •Female patients who have tested positive for lactation or serum pregnancy test during the screening period;
- •Received ASCT or had graft-versus-host disease in the past 12 months;
- •Suffering from moderate or severe persistent asthma within 2 years prior to enrollment, or having uncontrolled asthma at the time of enrollment;
- •Evidence of having other malignant tumors within the 3 years prior to enrollment or having been previously diagnosed with another malignant tumor with any residual lesions;
- •Suffering from chronic obstructive pulmonary disease (COPD), the forced expiratory volume (FEV1) in one second is less than 50% of the normal expected value;
- •Clinically significant heart disease, including:
- •Start studying myocardial infarction or unstable or uncontrollable conditions within 6 months prior to treatment (such as unstable angina, congestive heart failure, New York Heart Association (NYHA) III-IV);
- •Arrhythmias (NCI CTCAE V5.0 standard ≥ grade 3) or clinically significant electrocardiogram (ECG) abnormalities;
- •The electrocardiogram shows a baseline corrected QT (QTc) interval>470 ms;
- •Active infections, including but not limited to HAV, HBV, HCV, HIV;
- •Plasma cell leukemia (circulating plasma cells>2.0 × 10 ^ 9/L) or Waldenstrom macroglobulinemia (WM) or POEMS syndrome (multiple neuropathies, organ enlargement, endocrine disorders, monoclonal plasma cell disease, and skin changes);
- •Peripheral neuropathy or neuralgia of grade 2 or above (CTCAE 5.0 standard);
- •Underwent major surgery within 14 days prior to enrollment, or did not fully recover from early surgery, or planned surgery during the study period or within 14 days after the last study drug treatment (note: does not include surgery under local anesthesia or kyphoplasty or vertebroplasty);
- •According to the judgment of the investigator, there are concomitant diseases (such as active systemic infection, uncontrolled diabetes, acute diffuse invasive pulmonary disease, neurological or mental disease, etc.) or any other conditions that may confuse the research results or affect the completion of the study;
- •Individuals who are receiving any other experimental drugs or experimental medical devices;
- •The researchers believe that the patient has other circumstances that are not suitable for participation in this study.
研究组 & 干预措施
Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide, dexamethasone (DPd)
Experimental
Observed patients meeting the screening criteria were treated with Daratumumab/daratumumab and hyaluronidase-fihj + pomalidomide + dexamethasone regimen as appropriate.
Combined regimen of the above until disease progression or up to 2 years.
干预措施: Daratumumab/daratumumab and hyaluronidase-fihj (Drug)
Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide, dexamethasone (DPd)
Experimental
Observed patients meeting the screening criteria were treated with Daratumumab/daratumumab and hyaluronidase-fihj + pomalidomide + dexamethasone regimen as appropriate.
Combined regimen of the above until disease progression or up to 2 years.
干预措施: Pomalidomide (Drug)
Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide, dexamethasone (DPd)
Experimental
Observed patients meeting the screening criteria were treated with Daratumumab/daratumumab and hyaluronidase-fihj + pomalidomide + dexamethasone regimen as appropriate.
Combined regimen of the above until disease progression or up to 2 years.
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Hematologic Overall Remission Rate (ORR)
时间窗: A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.
ORR was defined as the proportion of subjects who achieved partial remission (PR) or better partial remission (VGPR) and complete response (CR) by Guideline 2021 Edition criteria.
次要结局
- Negative rate of microscopic residual disease (MRD)(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Hematologic complete remission (CR) rate(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Very good partial remission (VGPR) rate(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Overall survival (OS)(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Time to response (TTR)(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Progression free survival （PFS）(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
- Duration of response (DOR)(A follow-up is required 30 days (± 7 days) after the completion of all treatments, followed by a follow-up every 12 weeks (± 7 days) for a period of 1 year.)
研究者
Yongyong MA
Chief Physician of Hematology Department
First Affiliated Hospital of Wenzhou Medical University
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Daratumumab for Polyneuropathy Associated With MGUSMonoclonal Gammopathy of Undetermined SignificancePeripheral NeuropathyNCT06046287Georgetown University20
Unknown
2 期
Daratumumab in HLA Desensitization Prior to TransplantationCardiac TransplantNCT05300451Barry A. Boilson10
招募中
2 期
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLT-cell Acute Lymphoblastic LeukemiaNCT05289687Eastern Cooperative Oncology Group20
招募中
不适用
Daratumumab for Patients With Light Chain AmyloidosisLight Chain (AL) AmyloidosisNCT06376214Nanjing University School of Medicine100
尚未招募
不适用
Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple MyelomaNewly Diagnosed Multiple MyelomaNCT05561049The First Affiliated Hospital of Soochow University120